Watchmaker Genomics Licenses CRISPR Technology to Improve DNA Sequencing Efficiency
The company plans to use CRISPR-Cas9 as a binding tool to address bottlenecks in next-generation sequencing workflows.
The company plans to use CRISPR-Cas9 as a binding tool to address bottlenecks in next-generation sequencing workflows.
FlowMetric Diagnostics and Handyem have partnered to develop a mobile point-of-care diagnostic laboratory based on flow cytometry capabilities.